期刊
MOLECULES
卷 26, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/molecules26164927
关键词
amidinourea; herpes simplex virus; guanidine; antivirals; amidines
资金
- University of London (CW Maplethorpe Fellowship)
- Italian Ministry of Education
- University and Research-MIUR [PRIN 20178ALPCM]
- Cassa di Risparmio Foundation of Turin [2019.2273]
- University of Turin
A series of amidinourea compounds have been synthesized as potential non-nucleoside anti-HSV agents, showing micromolar activity against HSV-1 with low cytotoxicity. These compounds act in an early stage of the HSV replication cycle, just after viral attachment and entry.
Current therapy against herpes simplex viruses (HSV) relies on the use of a few nucleoside antivirals such as acyclovir, famciclovir and valacyclovir. However, the current drugs are ineffective against latent and drug-resistant HSV infections. A series of amidinourea compounds, designed as analogues of the antiviral drug moroxydine, has been synthesized and evaluated as potential non-nucleoside anti-HSV agents. Three compounds showed micromolar activity against HSV-1 and low cytotoxicity, turning to be promising candidates for future optimization. Preliminary mode of action studies revealed that the new compounds act in an early stage of the HSV replication cycle, just after the viral attachment and the entry phase of the infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据